NPPA directs State Drug Controllers to ensure smooth production, supply of Clofazimine for treatment of MDR TB
New Delhi: Through a recent notification, the National Pharmaceutical Pricing Authority (NPPA) has directed all State Drug Controllers (SDCs) to ensure smooth production and supply of clofazimine across the country used in the treatment of multidrug-resistant (MDR) TB.
Drug Clofazimine is a part of a regimen for the treatment of MDR TB under the National TB Elimination Program (NTEP) and there were references received from an advocacy group on a shortage of Clofazimine, which falls under the scheduled drug list.
Also Read: NPPA Raises MRP Of 21 Essential, Life-Saving Drugs By 50pc; Details
"The matter regarding shortage/ non-availability of the drug was taken up by NPPA with the Ministry of Health & Family Welfare (MoHFW). It has been confirmed by MoHFW that under NTEP they have a continuous supply of Clofazimine and there are sufficient stocks in the pipeline for future consumption. Also, no shortage/ non-availability of the drug has been reported by State Drug Controllers when asked in the matter, the NPPA notification read.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.